Status: Current Investments

Clinical-stage biotechnology company advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins.

Clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases.

Global HealthTech company that connects patients, physicians, trial sites, and BioPharma partners to enable earlier and better access to pre-approval treatments.

Clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.

Completed IPO in 2025

Clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases.

Clinical-stage biotechnology company working to develop potent and versatile tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.

Clinical-stage biotechnology company developing purpose-built therapeutics by leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology.

Clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis.

Clinical-stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases.

Completed IPO in 2025